Psoriasis-Targets and Therapy

metrics 2024

Connecting researchers to elevate psoriasis care globally.

Introduction

Psoriasis-Targets and Therapy is a leading open-access journal published by DOVE MEDICAL PRESS LTD, dedicated to advancing the knowledge and understanding of psoriasis treatment and management. Launched in 2011, this journal provides a platform for high-quality research that encompasses clinical studies, therapeutic advances, and novel targeted therapies for psoriasis. With a focus on the latest findings and innovative approaches, Psoriasis-Targets and Therapy serves as an essential resource for researchers, healthcare professionals, and students seeking to stay at the forefront of this dynamic field. The journal's commitment to open-access publishing ensures that critical insights and breakthroughs are readily available to the global medical community, fostering collaboration and progress in psoriasis treatment strategies. Researchers are encouraged to submit their findings to contribute to the growing body of knowledge that will ultimately improve patient care and outcomes.

Metrics 2024

SCIMAGO Journal Rank-
Journal Impact Factor5.20
Journal Impact Factor (5 years)4.30
H-Index-
Journal IF Without Self5.20
Eigen Factor0.00
Normal Eigen Factor0.13
Influence1.04
Immediacy Index0.90
Cited Half Life4.40
Citing Half Life3.70
JCI1.41
Total Documents-
WOS Total Citations444
SCIMAGO Total Citations-
SCIMAGO SELF Citations-
Scopus Journal Rank-
Cites / Document (2 Years)-
Cites / Document (3 Years)-
Cites / Document (4 Years)-

Metrics History

Rank 2024

IF (Web Of Science)

DERMATOLOGY
Rank 10/94
Percentile 89.90
Quartile Q1

JCI (Web Of Science)

DERMATOLOGY
Rank 11/94
Percentile 88.30
Quartile Q1

Quartile History

Similar Journals

AUSTRALASIAN JOURNAL OF DERMATOLOGY

Advancing skin science for a healthier tomorrow.
Publisher: WILEYISSN: 0004-8380Frequency: 4 issues/year

Australasian Journal of Dermatology is a leading publication in the field of dermatology, issued by Wiley since 1951, and reaching an audience of researchers, clinicians, and students interested in the latest advancements and practices in skin health. With an ISSN of 0004-8380 and an E-ISSN of 1440-0960, this journal stands out with its Q2 ranking in both Dermatology and Miscellaneous Medicine, positioning it within the top 61st percentile of its category according to Scopus. Although it does not provide Open Access options, Australasian Journal of Dermatology is committed to disseminating high-quality research that informs clinical practices and promotes scholarly dialogue. By publishing rigorous and peer-reviewed articles focused on various aspects of dermatological science, the journal plays a pivotal role in enhancing the dermatology community's understanding of skin conditions and treatments, making it an invaluable resource for professionals and students alike.

JOURNAL OF DERMATOLOGICAL TREATMENT

Opening doors to groundbreaking dermatological discoveries.
Publisher: TAYLOR & FRANCIS LTDISSN: 0954-6634Frequency: 8 issues/year

The JOURNAL OF DERMATOLOGICAL TREATMENT, published by TAYLOR & FRANCIS LTD, is a premier forum dedicated to advancing the field of dermatology through the dissemination of high-quality research. Since its inception in 1989, this journal has maintained a significant impact on the dermatological community, currently ranking in the top quartile (Q1) of the Dermatology category with an impressive Scopus ranking of #14 out of 142 journals, reflecting its reputation among peers and its contribution to the clinical and academic landscape. The journal shifted to Open Access in 2023, enhancing the accessibility of groundbreaking findings to researchers, clinicians, and students worldwide. With a commitment to publishing diverse articles, from innovative treatment modalities to comprehensive reviews, the JOURNAL OF DERMATOLOGICAL TREATMENT serves as an invaluable resource for professionals seeking to stay at the forefront of dermatological science in a rapidly evolving field.

Future Oncology

Unveiling groundbreaking findings in oncology.
Publisher: FUTURE MEDICINE LTDISSN: 1479-6694Frequency: 40 issues/year

Future Oncology is a premier peer-reviewed journal published by FUTURE MEDICINE LTD, dedicated to advancing research and innovation within the field of oncology. Established in 2005 and set to continue through 2024, this journal serves as an essential resource for researchers, healthcare professionals, and students engaged in cancer studies. With its emphasis on groundbreaking findings and multidisciplinary approaches, Future Oncology holds an esteemed reputation, reflected in its 2023 category quartiles ranking it in Q2 for Cancer Research and Q1 for Medicine (miscellaneous). The journal is indexed in Scopus, showcasing its rigorous content, with rankings in the 63rd percentile for Oncology and the 46th percentile for Cancer Research. Although it does not operate on an open-access model, its commitment to disseminating cutting-edge findings makes it an invaluable asset for those seeking to stay at the forefront of oncology research.Future Oncology strives to bridge the gap between laboratory and clinical research, fostering collaboration and appreciation for the complexities of cancer treatment.

JOURNAL OF CUTANEOUS MEDICINE AND SURGERY

Connecting research and clinical expertise in dermatology.
Publisher: SAGE PUBLICATIONS INCISSN: 1203-4754Frequency: 6 issues/year

The Journal of Cutaneous Medicine and Surgery is a premier publication in the fields of dermatology and surgery, dedicated to advancing the scientific understanding of skin-related conditions and surgical techniques. Published by SAGE Publications Inc, this esteemed journal features a rich repository of peer-reviewed research, reviews, and clinical studies, ensuring that it remains at the forefront of dermatologic and surgical innovation. With an impressive impact factor and a ranking in the top quartile (Q1) of both dermatology and surgery categories for 2023, it is recognized as a vital resource for professionals, researchers, and students alike. The journal has consistently made significant contributions to the knowledge base that guides clinical practice and surgical decision-making, fostering a deeper understanding of the complexities involved in cutaneous medicine. For comprehensive updates, researchers can access this journal through SAGE’s platform, which supports the dissemination of high-quality research findings to a global audience.

Blood and Lymphatic Cancer-Targets and Therapy

Championing Open Access for Global Cancer Research
Publisher: DOVE MEDICAL PRESS LTDISSN: 1179-9889Frequency: 1 issue/year

Blood and Lymphatic Cancer-Targets and Therapy, published by DOVE MEDICAL PRESS LTD, is a vital open-access journal that has been disseminating crucial research and findings in the field of hematology and oncology since 2011. With its ISSN 1179-9889, this journal focuses on the latest therapeutic targets and innovative treatment strategies for blood and lymphatic cancers, contributing significantly to the advancement of knowledge and practice in this specialized area. Designed for researchers, healthcare professionals, and students alike, Blood and Lymphatic Cancer-Targets and Therapy aims to foster a deeper understanding of cancer biology and promote collaborative efforts leading to novel therapeutic interventions. The open-access model ensures that research findings are readily accessible to a global audience, underscoring the journal's commitment to enhancing patient care and fostering educational growth in the cancer domain.

CLINICAL AND EXPERIMENTAL MEDICINE

Connecting Researchers and Practitioners for Better Health
Publisher: SPRINGER-VERLAG ITALIA SRLISSN: 1591-8890Frequency: 4 issues/year

Clinical and Experimental Medicine is a leading journal published by Springer-Verlag Italia SRL, dedicated to advancing the understanding of the intricate relationships between biomedical research and clinical applications. Since its inception in 2001, the journal has garnered an esteemed reputation, achieving Q1 quartile rankings in 2023 in both Biochemistry, Genetics and Molecular Biology (miscellaneous) and Medicine (miscellaneous), establishing itself as a key resource for researchers and practitioners alike. With an impactful contribution reflected in its Scopus rankings, particularly a #81/221 rank in the General Biochemistry, Genetics and Molecular Biology category, Clinical and Experimental Medicine serves as a rich platform for peer-reviewed articles that bridge theory and practice across diverse medical disciplines. The journal embraces Open Access options, broadening the accessibility of groundbreaking research to a global audience, thereby fostering collaboration and innovation. Located in Milan, Italy, it continually endeavors to enrich knowledge and share valuable insights essential for the advancement of health sciences.

International Cancer Conference Journal

Exploring New Horizons in Cancer Treatment and Prevention
Publisher: SPRINGER INT PUBL AGISSN: 2192-3183Frequency: 4 issues/year

International Cancer Conference Journal, published by Springer International Publishing AG, serves as a pivotal platform for the dissemination of cutting-edge research in the field of oncology. With a commitment to advancing the understanding, prevention, and treatment of cancer, this journal offers a forum for the presentation of innovative studies, clinical trials, and comprehensive reviews that cater to the needs of researchers, healthcare professionals, and students alike. Although currently not open access, the journal is dedicated to fostering collaboration and knowledge sharing within the cancer research community. The ISSN for this journal is 2192-3183, ensuring its listing within prominent academic databases for enhanced visibility. Hailing from Switzerland, the journal aspires to impact the global dialogue on cancer through rigorous peer-reviewed articles and special conference proceedings, making it an essential resource for those dedicated to the fight against cancer.

LANCET ONCOLOGY

Empowering the oncology community with cutting-edge knowledge.
Publisher: ELSEVIER SCIENCE INCISSN: 1470-2045Frequency: 12 issues/year

The Lancet Oncology is a premier peer-reviewed journal published by Elsevier Science Inc., recognized as a leading authority in the field of oncology. With an ISSN of 1470-2045 and E-ISSN 1474-5488, this esteemed journal boasts an impressive 2023 impact factor placing it in the Q1 category of oncology—reflecting its role as a critical resource for cutting-edge research. The journal publishes high-quality articles covering novel scientific discoveries, clinical advancements, and public health issues related to cancer treatment and prevention. It is ranked #5 out of 404 in the Scopus Medicine _ Oncology category, demonstrating its influence and relevance in the field, with an outstanding rank in the 98th percentile. Operating from its base in the United Kingdom, The Lancet Oncology spans a comprehensive timeframe from 2000 to 2024, making it a vital repository of oncology literature. Although it does not primarily operate on an open-access model, its significant subscription base ensures that a wealth of knowledge is accessible to researchers, professionals, and students alike, fostering a profound understanding and advancement in oncology.

Hepatic Oncology

Fostering Collaboration in Hepatic Oncology
Publisher: FUTURE MEDICINE LTDISSN: 2045-0923Frequency: 4 issues/year

Hepatic Oncology is a premier Open Access journal published by Future Medicine Ltd that specializes in the critical intersection of hepatology and oncology. With a focus on advancing knowledge in the diagnosis and treatment of liver cancers, the journal provides a platform for innovative research, reviews, and clinical perspectives that serve as a valuable resource for researchers, clinicians, and students alike. Established in 2016 and evolving over the years, Hepatic Oncology underscores its commitment to accessible scientific communication, having transitioned to open access in 2018 to reach a broader audience. The journal holds a Q4 quartile ranking in the fields of hepatology and oncology for 2023, reflecting its emerging influence and role in contemporary research. Through high-quality articles and a focus on real-world applications, Hepatic Oncology aims to bridge gaps in knowledge while fostering collaboration among professionals dedicated to enhancing patient care in hepatic malignancies.

Pediatric Rheumatology

Championing excellence in pediatric rheumatology research and practice.
Publisher: BMCISSN: Frequency: 1 issue/year

Pediatric Rheumatology is a leading peer-reviewed open access journal published by BMC, dedicated to disseminating high-quality research in the field of pediatric rheumatology. Since its inception in 2007, the journal has established itself as a vital resource for healthcare professionals, researchers, and students focused on pediatric immunology, rheumatology, and child health, maintaining an impressive Q1 ranking in Pediatrics and Q2 in Immunology and Allergy as well as Rheumatology for 2023. It is recognized for its impact on advancing knowledge and clinical practice, with significant contributions noted in various studies and case reports. With access options that embrace the ethos of open science, all articles published in Pediatric Rheumatology are freely available, promoting collaborative research and discussion among practitioners across the globe. The journal welcomes submissions that encapsulate innovative research, clinical trials, and reviews that address both current challenges and advancements within the pediatric rheumatology landscape.